Leap Therapeutics (NASDAQ: LPTX) adopts digital asset treasury strategy and private placement

Rhea-AI Filing Summary

Leap Therapeutics, Inc. reported that it has entered into a private placement and adopted a new digital asset treasury strategy. The company plans to maintain its existing biopharmaceutical business while also pursuing this digital asset approach to managing part of its treasury. These developments were first described in a press release dated October 6, 2025, which is attached as an exhibit to the report.

Insights

Biotech & Corporate Finance Analyst

Leap adds a private placement and a digital asset treasury strategy alongside its core business.

Leap Therapeutics is layering two corporate actions: a private placement and the adoption of a digital asset treasury strategy. The report makes clear that the company intends to continue its current line of business, so this is framed as an addition rather than a pivot away from its biopharma focus.

The private placement suggests access to capital from selected investors, but the size, pricing, and investor group are not detailed here and instead sit in the referenced press release. The digital asset treasury strategy signals that some portion of treasury management will now involve digital assets, which can entail different risk and volatility characteristics than traditional cash or securities.

Because no amounts, counterparties, or balance sheet proportions are disclosed in this excerpt, the overall impact is difficult to quantify. Future disclosures describing the scale of digital asset exposure and the terms of the private placement will be important for understanding how these steps affect liquidity, risk profile, and capital structure.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001509745 0001509745 2025-10-06 2025-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2025

Leap Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37990		27-4412575
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

47 Thorndike Street, Suite B1-1
Cambridge, MA 02141

(Address of Principal Executive Office) (Zip Code)

(617) 714-0360

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	LPTX	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On October 6, 2025, Leap Therapeutics, Inc. (the “Company”) issued a press release announcing a private placement and its adoption of a digital asset treasury strategy. The Company intends to continue to pursue its current line of business in addition to the pursuit of its digital asset treasury strategy.

A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1 and incorporated into this Item 8.01 by reference.

9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated October 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LEAP THERAPEUTICS, INC.
Date: October 6, 2025	/s/ Douglas E. Onsi
	Douglas E. Onsi
	President & CEO

FAQ

What did Leap Therapeutics (LPTX) announce in this 8-K?

Leap Therapeutics announced that it entered into a private placement and adopted a digital asset treasury strategy, while continuing its existing business.

Is Leap Therapeutics changing its core business with this digital asset strategy?

No. The company states it intends to continue its current line of business in addition to pursuing the digital asset treasury strategy.

How is Leap Therapeutics using digital assets according to this filing?

The company describes adopting a digital asset treasury strategy, indicating that digital assets will play a role in how it manages part of its treasury.

Where can investors find more details about Leap Therapeutics’ private placement?

More detail is contained in the press release dated October 6, 2025, which is attached as Exhibit 99.1 and incorporated by reference.

What exhibit did Leap Therapeutics attach to this 8-K?

Leap Therapeutics attached Exhibit 99.1, a press release dated October 6, 2025, and Exhibit 104, the cover page interactive data file.

Does this 8-K specify the financial terms of the private placement?

This excerpt only states that a private placement was announced and refers to the attached press release for details.